Zentalis Pharmaceuticals, Inc.

NasdaqGM:ZNTL Stock Report

Market Cap: US$87.1m

Zentalis Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:ZNTL Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
30 Apr 25BuyUS$29,373Scott MyersIndividual21,000US$1.40
06 Feb 25BuyUS$45,656Ingmar BrunsIndividual20,000US$2.28
03 Feb 25SellUS$22,643Andrea PaulIndividual13,230US$1.71
03 Feb 25SellUS$4,476Vincent VultaggioIndividual2,615US$1.71
03 Feb 25SellUS$24,591Mark LacknerIndividual14,368US$1.71
31 Jan 25BuyUS$49,345Julie EastlandIndividual28,500US$1.73
31 Jan 25BuyUS$103,446Jan SkvarkaIndividual60,000US$1.72
31 Jan 25BuyUS$24,966Luke WalkerIndividual14,200US$1.76
02 Jan 25SellUS$13,762Mark LacknerIndividual4,411US$3.12

Insider Trading Volume

Insider Buying: ZNTL insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ZNTL?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,005,9041.4%
Private Companies7,050,0009.8%
General Public7,172,4489.97%
Hedge Funds13,959,97319.4%
Institutions42,763,60959.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 74.7% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
19.4%
Matrix Capital Management Company, LP
13,959,973US$16.9m0%3.65%
9.8%
The Walters Group, Inc.
7,050,000US$8.5m76.3%no data
5.88%
BlackRock, Inc.
4,229,497US$5.1m-0.2%no data
4.53%
The Vanguard Group, Inc.
3,260,612US$3.9m-0.32%no data
4.27%
Millennium Management LLC
3,069,514US$3.7m221%no data
2.81%
Decheng Capital LLC
2,019,762US$2.4m-13.6%0.65%
2.76%
Opaleye Management Inc.
1,985,000US$2.4m12.3%0.53%
2.38%
Almitas Capital LLC
1,710,921US$2.1m5.16%0.41%
2.08%
Tang Capital Management, LLC
1,500,000US$1.8m0%0.09%
1.88%
Geode Capital Management, LLC
1,355,669US$1.6m3.25%no data
1.83%
State Street Global Advisors, Inc.
1,319,785US$1.6m2.39%no data
1.76%
PRIMECAP Management Company
1,264,620US$1.5m-16.8%no data
1.56%
Bank of America Corporation, Asset Management Arm
1,125,092US$1.4m433%no data
1.55%
D. E. Shaw & Co., L.P.
1,117,777US$1.4m-9.82%no data
1.48%
Acadian Asset Management LLC
1,067,233US$1.3m0%no data
1.34%
Tybourne Capital Management (HK) Ltd.
961,486US$1.2m0%4.37%
1.33%
Pfizer Venture Investments LLC
953,834US$1.2m0%0.22%
1.31%
Morgan Stanley, Investment Banking and Brokerage Investments
942,649US$1.1m-43.8%no data
1.17%
Two Sigma Advisers, LP
842,600US$1.0m-5.29%no data
1.15%
Renaissance Technologies LLC
826,041US$999.5k53.2%no data
1.05%
Federated Hermes, Inc.
752,517US$910.5k52.3%no data
1%
JPMorgan Chase & Co, Brokerage and Securities Investments
719,374US$870.4k37.6%no data
0.84%
AQR Capital Management, LLC
604,021US$730.9k174%no data
0.78%
Peapod Lane Capital LLC
558,418US$675.7k0%0.81%
0.76%
Two Sigma Investments, LP
549,334US$664.7k-10.9%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/22 01:41
End of Day Share Price 2025/05/22 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zentalis Pharmaceuticals, Inc. is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael SchmidtGuggenheim Securities, LLC
Andrew FeinH.C. Wainwright & Co.
Andres MaldonadoH.C. Wainwright & Co.